Clinical Trial Update: Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase II trial of a novel anti-angiogenic agent in combination with chemotherapy for non-small cell lung cancer; the study status is terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Non-small Cell Lung Cancer (NSCLC) | Phase 2 | Status: TERMINATED